← Russell 3000 cross-section

XGN EXAGEN INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$186m
Revenue TTM
$71m
Net income TTM
$-19m
Free cash flow
$-8m
Composite score
Sector rank
#2902

Valuation

P / E
EV / EBITDA
EV / sales
2.6
FCF yield
-4.08%
Earnings yield vs 10-yr
-14.89pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-26.6%
EBITDA margin
-15.2%
ROE
-154.9%
ROIC
-132.8%
Revenue growth
20.8%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the leadership of our Chief Executive Officer, John Aballi, who joined Exagen in October 2022, we have executed an operational turnaround of the business, resulting in a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn. All of our AVISEĀ® tests are performed in our approximately 13,000 square foot laboratory located in Vista, California, which is certified under the clinical laboratory testing administered by the Centers for Medicare & Medicaid Services (CLIA) and accredited by the College of American Pathologists. …EXAGEN INC., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →